Improvement of psoriatic arthritis by pioglitazone treatment in a type 2 diabetic patient.
Takahara
M
M
Shiraiwa
T
T
Kaneto
H
H
Yasuda
T
T
Kuroda
A
A
Sakamoto
F
F
Naka
T
T
Miyashita
K
K
Sakamoto
K
K
Matsuoka
T
T
Shimomura
I
I
Matsuhisa
M
M
D015535:Arthritis, Psoriatic / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D002097:C-Reactive Protein / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D000077205:Pioglitazone; D012720:Severity of Illness Index; D045162:Thiazolidinediones / Q000627:therapeutic use*
D002097:C-Reactive Protein; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D045162:Thiazolidinediones; C517652:hemoglobin A1c protein, human